| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 189.02% | Maxim Group | → $5 | Upgrades | Hold → Buy |
| 06/26/2023 | 593.64% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 06/07/2023 | 593.64% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 12/30/2022 | 73.41% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 07/26/2022 | -42.2% | Maxim Group | → $1 | Upgrades | Hold → Buy |
| 07/11/2022 | 189.02% | HC Wainwright & Co. | $2.5 → $5 | Maintains | Buy |
| 04/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 11/03/2021 | 44.51% | HC Wainwright & Co. | $3.5 → $2.5 | Maintains | Buy |
| 09/13/2021 | 102.31% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
| 07/27/2021 | 189.02% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 12/08/2020 | 304.62% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 03/20/2020 | 246.82% | HC Wainwright & Co. | $7 → $6 | Reiterates | → Buy |
| 02/18/2020 | 304.62% | HC Wainwright & Co. | $5 → $7 | Maintains | Buy |
| 02/18/2020 | 362.43% | RBC Capital | $5 → $8 | Maintains | Outperform |
| 06/07/2019 | 189.02% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 11/29/2018 | 73.41% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
What is the target price for Agile Therapeutics (AGRX)?
The latest price target for Agile Therapeutics (NASDAQ: AGRX) was reported by Maxim Group on September 22, 2023. The analyst firm set a price target for $5.00 expecting AGRX to rise to within 12 months (a possible 189.02% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Agile Therapeutics (AGRX)?
The latest analyst rating for Agile Therapeutics (NASDAQ: AGRX) was provided by Maxim Group, and Agile Therapeutics upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Agile Therapeutics (AGRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agile Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agile Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
Is the Analyst Rating Agile Therapeutics (AGRX) correct?
While ratings are subjective and will change, the latest Agile Therapeutics (AGRX) rating was a upgraded with a price target of $0.00 to $5.00. The current price Agile Therapeutics (AGRX) is trading at is $1.73, which is within the analyst's predicted range.